Robert S Keane sold $1.9M of ATRO
director at ASTRONICS CORP. 77,099 shares at an average of $24.55, traded Mar 7, 2025, filed Mar 11, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.9M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-011976, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 7, 2025 | SOpen-market sale $.01 PV Com Stkindirect: Note | -26,041 | $24.55 | $639k | 0 | Mar 11, 2025 |
| Mar 7, 2025 | SOpen-market sale $.01 PV Com Stkindirect: Note | -51,058 | $24.55 | $1.3M | 0 | Mar 11, 2025 |
Related signals
Other insiders at ASTRONICS CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ATROsell ASTRONICS CORP | James Mulato other | $518k 9,734 shares | -26% | |
| 14Weak | ATROsell ASTRONICS CORP | James Mulato other | $43k 1,129 shares | -3% | |
| 60Notable | ATROsell ASTRONICS CORP | Robert S Keane director | $6.4M 237,700 shares | -119% | |
| 15Weak | ATROsell ASTRONICS CORP | Mark Peabody Executive VP & Pres-Aerospace | $8,050 511 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.